Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.
|
18641190 |
2008 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As IRF-3 is downstream from the TLR4 adaptor TIR-domain-containing adapter-inducing IFN-beta (Trif), we demonstrate that macrophages from Trif-/- mice are resistant to this dysregulation of TNF-alpha transcription by EtOH in vitro as well as EtOH-induced steatosis and TNF dysregulation in vivo.
|
18713975 |
2008 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Liver NF-kappaB and AP-1 DNA binding were markedly increased in NASH patients (n = 9; P < 0.05) compared to controls, without significant changes in NAFLD patients with steatosis (n = 8), whereas TLR4 expression was comparable between groups.
|
19165171 |
2009 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have shown that mice deficient in IRF3 or TLR4 expression are protected from alcohol-induced liver steatosis, inflammation and hepatocyte injury.
|
23075869 |
2012 |
Steatohepatitis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent reports have suggested that PNPLA3, IL28B and TLR4-associated single nucleotide polymorphisms (SNPs) may have an impact on hepatic steatosis or fibrosis in patients with chronic HCV infection.
|
24349054 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
All of these findings demonstrated that BA or BT might ameliorate acute ethanol-induced fatty liver via TLR4 and STAT3 in vivo and in vitro, promising agents for ethanol-induced fatty liver therapies.
|
23816536 |
2013 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
CTD_human |
TLR4 on macrophages contributes to the development of steatohepatitis-related HCC in mice.
|
27022031 |
2016 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatic steatosis was decreased 32-fold in the absence of TLR4.
|
28351520 |
2017 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Methionine-choline-deficient mice given 5% fructo-oligosaccharides exhibited significantly decreased hepatic steatosis (p = 0.003), decreased liver inflammation (p = 0.005), a decreased proportion of CD14-positive Kupffer cells (p = 0.01), decreased expression of TLR4 (p = 0.04), and increases in fecal short-chain fatty acid and IgA concentrations (p < 0.04) compared with the findings in methionine-choline-deficient mice that were not administered this prebiotic.
|
28632732 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic and pharmacological suppression of the LPS-TLR4 pathway or transplantation with Tlr4<sup>-/-</sup> bone-marrow-derived hematopoietic cells increases beige fat development and ameliorates diet-induced fatty liver, while Tlr4<sup>-/-</sup> or microbiota-depleted mice are resistant to further CR-stimulated metabolic alterations.
|
30174308 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that selective hepatocyte TLR4 deletion protected mice from chronic alcohol-induced liver injury and fatty liver.
|
29884546 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis.
|
30034633 |
2018 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated the molecular mechanism of steatosis and the role of mitogen-activated protein kinase (MAPK)/toll-like receptor 4-related protein (TLR4) expression in this study.
|
31264285 |
2019 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Intestinal permeability, hepatic steatosis and mRNA and protein expressions of TLR4-related inflammatory signaling molecule were analyzed.
|
31788011 |
2019 |